UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
April 10, 2018 at 08:38 AM EDT
April 10 (Reuters) - AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.